• FMC Corporation’s recent index reshuffle saw it drop from several Russell large- and mid-cap benchmarks while being added to the Russell 2000 family, alongside a new co-exclusive supply and license agreement allowing Corteva to commercialize FMC’s rimisoxafen herbicide technology across North and South American corn and soybean markets.
• The agreement, which runs into the next decade and includes a US$200 million prepurchase payment from Corteva, underlines the commercial importance of rimisoxafen within FMC’s crop protection portfolio and broadens future market access while FMC retains ownership of the underlying technology.
• We’ll now examine how FMC’s move into Russell small-cap indices and the rimisoxafen partnership with Corteva reshape the company’s investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

FMC Investment Narrative Recap

To own FMC today, you need to believe the company can turn an unprofitable, highly leveraged crop protection business into a healthier, innovation‑driven platform while managing pricing, regulatory and generic pressures. The shift from Russell large and mid‑cap indices into Russell 2000 benchmarks and the rimisoxafen deal with Corteva do not materially change the near term focus on restoring margins and reducing net leverage, which remain the key catalyst and core risk.

The rimisoxafen supply and license agreement with Corteva stands out here. Corteva’s US$200 million prepurchase payment provides additional liquidity as FMC works through earnings weakness and elevated net debt, while FMC keeps ownership of the underlying technology. With first sales expected later this decade, the deal fits into the existing catalyst of new product introductions, but investors still need to watch how quickly this translates into profitable, cash‑generative growth.

Yet behind this product story, investors should also be aware of the mounting pressure from tighter pesticide regulation and shifting farming practices that could...

FMC's narrative projects $4.0 billion revenue and $286.1 million earnings by 2029.

Uncover how FMC's forecasts yield a $17.53 fair value, a 49% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most bearish analysts were already assuming only about 4.6 percent annual revenue growth and US$271.9 million earnings by 2029, so this latest news may either soften or reinforce that more cautious narrative depending on how you judge FMC’s ability to offset regulatory and pricing risks.

Explore 5 other fair value estimates on FMC - why the stock might be worth as much as 100% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your FMC research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free FMC research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FMC's overall financial health at a glance.

Searching For A Fresh Perspective?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.